Cancer biomarkers are generally biological molecules found in blood, other body fluids, or tissues that are a signal of a normal or abnormal process, or of a stipulation or disease. The cancer biomarkers are used for drug discovery and development, diagnostics, personalized medicine, and therapeutics. The most recent designed biomarkers and their applications give a great benefit in the cancer cases.
The cancer diagnostics market is driven by increasing commonness of different forms of cancer, growing cancer awareness, support of government initiatives and funding, and rise in healthcare expenditure. The introduction of non-invasive screening methods and novel diagnostic biomarkers are likely to create new revenue streams and fuel the cancer diagnostics market over the next five years. However, vague reimbursement scenario in certain countries and lack of specificity and sensitivity threaten to obstruct the growth of the cancer diagnostics market.
The Europe cancer biomarkers market is segmented on the basis of disease into Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer and Other Cancers. Based on services market is divided into Sample Preparation, Assay development and Biomarkers validation and testing. On the basis of application, market is bifurcated into Risk Assessment, Development of molecular diagnostics, Disease diagnosis, Drug discovery and Development and Drug formulation. By Type, the cancer biomarkers market is segregated into Protein Biomarkers, Genetic biomarkers and other biomarkers. Based on profiling technologies, segmentation is among omics technologies, Imaging technologies, Immunoassays, Cytogenetics, Bioinformatics and IVD multivariate index assays. Omics technologies segment is further sub segmented into Genomics, Proteomics, Metabolomics, Transcriptomics and Pharmacogenomics.
Get accurate market forecast and analysis on the Europe Cancer Biomarkers Market Request a sample to stay up-to-date on the main trends affecting this market:
Based on geography, the market is analysed under various countries namely, U.K., Germany, France, Italy and Spain. U.K. is leading the cancer biomarkers market due to high incidence of cancer cases.
Some of the major players in this market are Abbott Laboratories, Agendia Bv, Biocurex Inc, Biomerieux S.A., Biomoda Inc, Astellas Pharma Us Inc, Correlogic Systems Inc, Beckman Coulter Inc, Becton, Dickinson And Company, Clarient Inc, Diadexus Inc, Ambrilia Biopharma, Affymetrix Inc and Aureon Laboratories Inc.
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com.